Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.41 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.41 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.41 |
| ▸ | KCNA3 known ✓ | P22001 | 3/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.33 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3360995 | 0.99 | MAOA (0.42) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL4194803 | 0.94 | MAOA (0.44) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3359666 | 0.93 | MAOA (0.45) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL7744392 | 0.88 | MAOB (0.41) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL4193524 | 0.85 | MAOA (0.41) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL4188117 | 0.84 | MAOA (0.40) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3359444 | 0.84 | MAOA (0.41) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL8903963 | 0.83 | MAOA (0.41) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3360003 | 0.83 | MAOA (0.41) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL7524945 | 0.81 | MAOB (0.40) | MAOAMAOBKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0840781-B1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-1776952-A2 | Photodecontamination of pathogens in blood | Cerus Corporation (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1584622-A2 | Compounds for the photodecontamination of pathogens in blood | Cerus Corporation (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20030185804-A1 | Compounds for the photodecontamination of pathogens in blood | CERUS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
| US-6544727-B1 | Deactivating nucleic acid pathogens | CERUS CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-6503699-B1 | Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound | CERUS CORPORATION | 2003-01-07 | — | — | US | disclosed |
| US-20020192632-A1 | Method and devices for the removal of psoralens from blood products | HEI DEREK J (US) | 2002-12-19 | — | — | US | disclosed |
| US-6469052-B2 | PSORALEN COMPOUNDS HAVE SUBSTITUTIONS ON THE 4, 4', 5', AND 8 POSITIONS WHICH PERMIT ENHANCED BINDING OF NUCLEIC ACID OF PATHOGENS | CERUS CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-20020115585-A1 | Method and devices for the removal of psoralens from blood products | HEI DEREK J (US) | 2002-08-22 | — | — | US | disclosed |
| US-6420570-B1 | THE PRESENT INVENTION CONTEMPLATES METHODS OF INACTIVATING MICROORGANISMS IN BLOOD PREPARATIONS, BLOOD PREPARATION SUSPECTED OF BEING CONTAMINATED WITH A PATHOGEN HAVING NUCLEIC ACID | CERUS CORPORATION | 2002-07-16 | — | — | US | disclosed |
| US-5593823-A | FOR A SUFFICIENT DURATION, INTENSITY AND WAVELENGTH | CERUS CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996040857-A1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996039820-A1 | METHODS OF INACTIVATING LEUKOCYTES AND INHIBITING CYTOKINE PRODUCTION IN BLOOD PRODUCTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5585503-A | PSORALEN COMPOUNDS | STERITECH, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5578736-A | SUBSTITUTED PSORALENS | STERITECH, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5556993-A | PSORALEN COMPOUNDS FOR DEACTIVATION OF HEPATITIS AND HIVVIRUSES | STERITECH, INC. (US) | 1996-09-17 | — | — | US | disclosed |
| WO-1996014739-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | CERUS CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0707476-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5399719-A | 4'-/4-Amino-2-oxa/butyl-4,5',8-trimethylpsoralen; preparation of 4'-/omega-amino-2-oxa/alkyl-4,5',8-trimethylpsoralens by reacting analogous omega-hydroxy compound with methanesulfonyl chloride and base, with sodium azide, with reducing agent | STERITECH, INC. (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1995000141-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185804-A1 | Compounds for the photodecontamination of pathogens in blood | HMBS, HLA-C, HLA-B | MAOA 2397/4885MAOB 2018/4885HTR2C 4081/4885 |
| US-20020115585-A1 | Method and devices for the removal of psoralens from blood products | SERPINB10, RAD50, F2 | MAOA 2515/4885MAOB 2849/4885HTR2C 4463/4885 |
| US-20020192632-A1 | Method and devices for the removal of psoralens from blood products | PLG, SERPINB10, RAD50 | MAOA 2207/4885MAOB 2651/4885HTR2C 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.